Tumor cell settling and early invasion of the peritoneum

Molengraft, Fred van de; Jap, P. H. K.; Poels, L. G.; Croes, H.J.E.; Vooijs, P.

doi:10.1007/bf01787023

Cited by 4 publications

(3 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The overlying mesothelium is still preserved in early and very small lesions, whereas in later phases it reacts in the form of papillary microprojections or shows erosions, followed by a perifocal fibrinous peritonitis. Similar findings have been obtained in animal models (van de Molengraft et al 1989).…”

Section: Peritoneal Metastasessupporting

confidence: 89%

Invasion Patterns and Metastatic Patterns of Hepatocellular Carcinoma

Zimmermann

2016

Tumors and Tumor-Like Lesions of the Hepatobiliary Tract

View full text Add to dashboard Cite

show abstract

Section: Peritoneal Metastasessupporting

confidence: 89%

Invasion Patterns and Metastatic Patterns of Hepatocellular Carcinoma

Zimmermann

2016

Tumors and Tumor-Like Lesions of the Hepatobiliary Tract

View full text Add to dashboard Cite

show abstract

“…This fibrin gel matrix might also help provide the matrix that facilitates the ingrowth of macrophages and fibroblasts and reorganizes the stroma, preparing it for tumor metastasis to the abdominal cavity (41,42) . It is interesting that plasma exudates that contribute to ascites, generally remain fluid and do not form an insoluble fibrin gel until they are removed from the patient (43) .…”

Section: Vte and Ovarian Cancermentioning

confidence: 99%

Venous thromboembolism syndrome in gynecological cancer

Wang¹,

Fu²,

Freedman³

et al. 2006

International Journal of Gynecological Cancer

View full text Add to dashboard Cite

Venous thromboembolism (VTE) could be presented as an initial clinical feature in some cancer patients or a complication followed by various cancer treatments, which all indicates a poor outcome. This review focuses on elucidating the relationship of VTE and the main gynecological cancers including ovarian, endometrial, and cervical cancers. First, the general VTE information about gynecological cancer are introduced; second, the risk factors of VTE developing in gynecological cancer were discussed; third, we do a retrospective analysis on a novel treatment targeting coagulation cascade; and last, we analyze VTE as a remarkable complication followed by recombinant human erythropoietin and anti-vascular endothelial growth factor treatment in gynecological cancer patients. In summary, the interaction between the coagulation system and cancer progression is a novel promising area to be explored in the study of VTE in patients with gynecological cancer.

show abstract

“…Fibrin in the tumor or elsewhere in the peritoneum and serosa might help stimulate the new ingrowth of blood vessels. This fibrin gel matrix might also help provide the matrix that facilitates the ingrowth of MAs and fibroblasts and reorganizes the stroma, preparing it for tumor metastasis to the abdominal cavity [129,130]. Ascitic tumor cells as well as tumor cells derived from peritoneal and serosal surfaces can retain their viability in suspension cultures [131].…”

Section: Introductionmentioning

confidence: 99%

Ovarian cancer, the coagulation pathway, and inflammation

et al. 2005

View full text Add to dashboard Cite

Epithelial ovarian cancer (EOC) represents the most frequent cause of death in the United States from a cancer involving the female genital tract. Contributing to the overall poor outcome in EOC patients, are the metastases to the peritoneum and stroma that are common in this cancer. In one study, cDNA microarray analysis was performed on fresh tissue to profile gene expression in patients with EOC. This study showed a number of genes with significantly altered expression in the pelvic peritoneum and stroma, and in the vicinity of EOC implants. These genes included those encoding coagulation factors and regulatory proteins in the coagulation cascade and genes encoding proteins associated with inflammatory responses. In addition to promoting the formation of blood clots, coagulation factors exhibit many other biologic functions as well as tumorigenic functions, the later including tumor cell proliferation, angiogenesis, invasion, and metastasis. Coagulation pathway proteins involved in tumorigenesis consist of factor II (thrombin), thrombin receptor (protease-activated receptors), factor III (tissue factor), factor VII, factor X and factor I (fibrinogen), and fibrin and factor XIII. In a recent study we conducted, we found that factor XII, factor XI, and several coagulation regulatory proteins, including heparin cofactor-II and epithelial protein C receptor (EPCR), were also upregulated in the peritoneum of EOC.In this review, we summarize evidence in support of a role for these factors in promoting tumor cell progression and the formation of ascites. We also discuss the different roles of coagulation factor pathways in the tumor and peritumoral microenvironments as they relate to angiogenesis, proliferation, invasion, and metastasis. . Since inflammatory responses are another characteristic of the peritoneum in EOC, we also discuss the linkage between the coagulation cascade and the cytokines/chemokines involved in inflammation. Interleukin-8, which is considered an important chemokine associated with tumor progression, appears to be a linkage point for coagulation and inflammation in malignancy. Lastly, we review findings regarding the inflammatory process yielded by certain clinical trials of agents that target members of the coagulation cascade in the treatment of cancer. Current data suggest that disrupting certain elements of the coagulation and inflammation processes in the tumor microenvironment could be a new biologic approach to cancer therapeutics.

show abstract

Tumor cell settling and early invasion of the peritoneum

Cited by 4 publications

References 21 publications

Invasion Patterns and Metastatic Patterns of Hepatocellular Carcinoma

Invasion Patterns and Metastatic Patterns of Hepatocellular Carcinoma

Venous thromboembolism syndrome in gynecological cancer

Ovarian cancer, the coagulation pathway, and inflammation

Contact Info

Product

Resources

About